Summary
Abbott Laboratories' 2014 10-K filing reveals a company undergoing significant strategic transformations. A major development was the completed separation of its research-based pharmaceuticals business into AbbVie Inc. on January 1, 2013. More recently, the company announced the sale of its developed markets branded generics pharmaceuticals business to Mylan Inc., which closed shortly after the reporting period. These strategic moves indicate a focus on streamlining operations and concentrating on core growth areas such as nutritional products, diagnostics, and vascular devices, with a significant emphasis on emerging markets. The company also made several key acquisitions, including CFR Pharmaceuticals in Latin America and Veropharm in Russia, to bolster its presence in these growing regions. Despite ongoing pricing pressures and regulatory complexities inherent in the healthcare industry, Abbott demonstrated resilience, with sales growth driven by its nutritional and diagnostics segments.
Financial Highlights
54 data points| Revenue | $20.25B |
| Cost of Revenue | $9.22B |
| Gross Profit | $11.03B |
| SG&A Expenses | $6.53B |
| Operating Expenses | $17.65B |
| Operating Income | $2.60B |
| Interest Expense | $150.00M |
| Net Income | $2.28B |
| EPS (Basic) | $1.50 |
| EPS (Diluted) | $1.49 |
| Shares Outstanding (Basic) | 1.52B |
| Shares Outstanding (Diluted) | 1.53B |
Key Highlights
- 1Abbott completed the separation of its research-based proprietary pharmaceuticals business into AbbVie Inc. on January 1, 2013, creating two distinct publicly traded companies.
- 2The company announced the sale of its developed markets branded generics pharmaceuticals business to Mylan Inc. in July 2014, with the transaction closing shortly after the reporting period (February 27, 2015).
- 3Abbott made significant strategic acquisitions to expand its reach in emerging markets, including CFR Pharmaceuticals S.A. (Latin America) for approximately $2.9 billion and Veropharm (Russia) for approximately $315 million.
- 4The nutritional and diagnostics businesses were key drivers of sales growth and margin improvement over the last three years.
- 5Emerging markets represented nearly 50% of total company sales and experienced robust growth, with sales increasing 12.5% in 2014 and 10.8% in 2013, excluding foreign exchange impacts.
- 6The company's vascular business faced pricing pressures, particularly in drug-eluting stents, leading to flat sales in 2013 and 2014, though new product introductions and market penetration provided some growth.
- 7Abbott continued its commitment to returning capital to shareholders, increasing its quarterly dividend by 40% in 2014 and announcing share repurchase programs.